1. Record Nr. UNINA9910807355903321

Autore	Randleman J. Bradley
Titolo	Refractive surgery : an interactive case-based approach / / J. Bradley Randleman
Pubbl/distr/stampa	Thorofare, New Jersey : , : SLACK Incorporated, , 2014 ©2014
ISBN	9781630910228 1-63091-022-8
Descrizione fisica	1 online resource (240 p.) : color illustrations
Disciplina	617.755
Soggetti	Eye - Accommodation and refraction Refractive keratoplasty
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references.
Sommario/riassunto	"Refractive Surgery : An Interactive Case-Based Approach presents all of the necessary refractive surgery material to make an informed decision regarding diagnosis and management plans. Rather than utilizing the standard organization of most books, where major points are first introduced and then explained through a series of writings and references, this book relies on the clinical decision-making process involved with treating refractive surgery patients. Refractive Surgery: An Interactive Case-Based Approach by Dr. J. Bradley Randleman builds upon foundational initial chapters through the case presentations and focused case discussions, encompassing the major topics in refractive surgery today. For each case, the critical question is simply, "what data in this chart is the most critical to consider when evaluating this patient for surgery?" Refractive Surgery: An Interactive Case-Based Approach is unique in its format. Specifically, the book facilitates active learning by forcing the reader to think through a series of questions surrounding each patient scenario. This active learning not only facilitates better recall of the information presented but also mimics the actual physician-to-patient clinical experience, making this book more relevant than other routine refractive surgery books. Bonus! This

	dynamic learning tool is also supplemented by interactive online video material to further the learning experience. Enhance the clinical decision-making process by watching the videos and then answering a series of questions that lead to the conclusion of each scenario"--Provided by publisher.

2.

Record Nr.	UNINA9911019658503321
Autore	Sofia Michael J
Titolo	Trends in Antiviral Drug Development
Pubbl/distr/stampa	Newark : , : John Wiley & Sons, Incorporated, , 2025 ©2025
ISBN	3-527-84509-7 3-527-84510-0 3-527-84508-9
Edizione	[1st ed.]
Descrizione fisica	1 online resource (531 pages)
Collana	Trends in Drug Discovery Series
Altri autori (Persone)	WangZhengqiang FischerJános KleinChristian ChildersWayne E RotellaDavid P
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Cover -- Half Title Page -- Title Page -- Copyright -- Contents -- Preface -- Introduction: Successes and Challenges in Antiviral Drug Development -- Introduction -- Antiviral Drugs Targeting Human Herpesviruses -- Antiviral Drugs Targeting Human Immunodeficiency Virus -- Drugs Targeting Reverse Transcriptase -- Drugs Targeting Protease -- Drugs Targeting Integrase Strand Transfer -- Drugs Targeting Viral Entry -- Drugs Targeting Viral Capsid -- Antiviral Drugs Targeting Hepatitis B Virus -- Antiviral Drugs Targeting Hepatitis Delta Virus -- Antiviral Drugs Targeting Hepatitis C Virus -- Antiviral Drugs Targeting Acute RNA Respiratory Viruses -- Drugs Targeting Human

Influenza Viruses -- Drugs Targeting SARS-CoV-2 -- New Trends and Challenges in Antiviral Drug Development -- References -- Part I: Human Herpes Viruses -- Chapter 1: Letermovir for the Prevention of CMV Infection in Transplant Recipients -- 1.1 Background -- 1.1.1 Cytomegalovirus -- 1.1.2 Immunocompromised Patients -- 1.1.3 Patient Groups with a High Risk for CMV Complications -- 1.1.4 Available CMV Treatments Before Letermovir -- 1.1.4.1 Antiviral Drugs -- 1.1.4.2 Dominant Treatment Strategies -- 1.1.4.3 Unmet Medical Need -- 1.2 Discovery Phase -- 1.3 Preclinical Characterization -- 1.3.1 Antiviral Potency/Selectivity/Inhibitory Profile -- 1.3.1.1 In Vitro Potency Versus Laboratory CMV Strains -- 1.3.1.2 In Vitro Potency Versus Clinical CMV Isolates and Resistance-breaking Profile -- 1.3.1.3 In Vivo Efficacy (Xenotransplant Model) -- 1.3.1.4 In Vitro Antiviral Specificity -- 1.3.1.5 Other Characteristics of Letermovir's Inhibitory Profile -- 1.3.1.6 Summary -- 1.4 Mechanism of Action Studies -- 1.4.1 Target Identification -- 1.5 Terminase Inhibitors -- 1.5.1 Previous and Contemporary Drug Candidates Targeting the Terminase Complex.
1.5.2 Letermovir: Same Target, Different Interaction -- 1.5.3 Advantages of Terminase Inhibitors -- 1.6 Preclinical Safety Evaluation -- 1.7 Clinical Development and MAA/NDA Submission -- 1.7.1 Regulatory Support for Clinical Development -- 1.7.2 Phase 1 -- 1.7.2.1 Drug-Drug Interaction Studies -- 1.7.2.2 Special Populations -- 1.7.2.3 IV Formulation -- 1.7.3 Clinical Proof-of-concept -- 1.7.3.1 Phase 2a Clinical Trial (AIC001-2-001) -- 1.7.3.2 Emergency IND Treatment of a Lung Transplant Patient with Multiresistant CMV Disease -- 1.7.3.3 Credentials Established -- 1.7.4 Letermovir for CMV Prophylaxis in HSCT Patients -- 1.7.4.1 Phase 2b: First Prophylaxis Trial in HSCT Patients -- 1.7.4.2 Phase 3 CMV Prophylaxis Trial in HSCT Patients -- 1.7.4.3 Marketing Approval in HSCT Recipients -- 1.7.4.4 Further Clinical Development and Real-world Data -- 1.7.4.4.1 Phase 3 Trial for Extension of the Prophylaxis Period -- 1.7.4.4.2 Follow-up Trials in Specific Populations -- 1.7.5 Letermovir for CMV Prophylaxis in KT Patients -- 1.7.5.1 Phase 3 Noninferiority Trial in KT Recipients -- 1.7.5.2 Marketing Approval in KT Recipients -- 1.7.5.3 Further Clinical Development and Real-world Data -- 1.8 Drug Resistance -- 1.8.1 Genetic Characterization of Letermovir Resistance -- 1.9 Letermovir Resistance in Clinical Trials -- 1.10 Real-world Resistance -- 1.11 Outlook for Letermovir -- Acknowledgments -- References -- Chapter 2: Discovery and Development of the Helicase-Primase Inhibitor Pritelivir for the Treatment of Immunocompromised Patients with Resistant HSV Infection -- 2.1 HSV Virology and Disease -- 2.2 Treatment -- 2.3 Resistant Infections -- 2.4 Pritelivir Discovery and Target Identification -- 2.5 Nonclinical Data -- 2.5.1 In Vitro Studies -- 2.5.2 In Vivo Studies -- 2.5.2.1 Guinea Pig Model for Genital HSV-2 Infection -- 2.5.2.2 Mouse Model for HSE.
2.5.2.3 Pritelivir in Immunocompromised Mouse Model -- 2.6 Clinical Data -- 2.6.1 Phase 1 Program -- 2.6.2 Genital HSV -- 2.6.3 Resistant Infections -- 2.7 Pritelivir Resistance -- 2.8 Conclusion and Outlook -- References -- Part II: Immunodeficiency Virus -- Chapter 3: The Discovery and Early Development of the HIV-1 Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572) -- 3.1 Introduction -- 3.2 Medicinal Chemistry -- 3.2.1 Discovery of S/GSK1349572 (DTG) -- 3.2.1.1 Evolution of the Chemical Structure Leading to DTG -- 3.3 Virology -- 3.3.1 In Vitro Studies Indicated Robust Efficacy and High Barrier to Resistance of DTG -- 3.4 Clinical Development -- 3.4.1 PK Studies Supported Once-daily 50 mg Dosing of DTG -- 3.4.2 Clinical Studies in People Living with HIV-1 -- 3.4.3 Clinical Studies in